Giving first glimpse of data, Scancell looks for Covid-19 vaccine partner

13 Feb 2023
endpts.com
VaccinePhase 1Clinical ResultmRNAEmergency Use Authorization
UK-based biotech Scancell is lifting the veil off a Phase I trial for its Covid-19 vaccineCovid-19 vaccine, but it’ll also be making a pivot on the vaccine’s strategy. Scancell said in a release on Monday that it is presenting the preliminary data from its Phase I clinical trial, which was conducted at the University of Cape Town Lung Institue in South Africa. The trial was intended to look at two of vaccine Scancell’s candidates, SCOV1 and SCOV2, in patients before testing them as a booster. According to the biotech, both candidates are plasmid DNA-based vaccines. The results showed antibody and T cell responses, with the level of the detectable antibodies in the blood at 67% following vaccination by the two candidates. Scancell also stated that the vaccines had an impact against several variants, including Omicron. No severe effects or major safety issues were reported during the trial. But Scancell said in the release that it will not be going to take the vaccine forward on its own. Because of the larger size of later-stage trails and the competitiveness of the current Covid-19 field, the biotech will be looking for a partner. Scancell CEO Lindy Durrant said in the release: However, no details on potential partners or when Scancell will be transferring the candidate were disclosed. Endpoints News reached out to the biotech for more information. The Covid-19 market has changed quite drastically since the big vaccine pushes a few years ago. Pharma giant Pfizer said on its Q4 earnings call that it is expecting much lower sales of Covid-19 products due to a lower following of compliance with vaccine regulations and fewer vaccines being administered, among other factors. This is leading to an anticipated drop of around 60% in vaccine sales revenue. Last week, Japan canceled an order for more than 140 million doses of Novavax’s Covid-19 vaccineCovid-19 vaccine, after agreeing to purchase around 150 million doses from Takeda in 2021. Takeda CFO Costa Saroukos said on a previous call that it is seeing “low market demand” for the vaccine due to vaccination in Japan and the Omicron variant’s presence.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.